Journey Medical Corporation DERM R2K
Company Overview
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Recent Developments
- Dec 2025 Revenue of $61.24M (+11.1% YoY); net profit $-11.43M.
- Trailing 12 Months Year-on-year growth — revenue +21.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 6.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 6.58% |
| 1 Year: | 21.50% |
Stock Price Performance
| 1 Year: | -3.91% |
| 6 Months: | -2.06% |
| 3 Months: | +36.92% |
| 1 Month: | +13.56% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)60.05 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DERM Journey Medical Corporation R2K | 7.12 | -19.24 | $153.33M | 0.00% | -14.30% | -36.62% | 6.58% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.45M | 10.72M | 15.29M | 19.61M | 20.80M | 18.23M | 16.04M | 12.16M | 16.96M | 15.28M | 13.03M | 14.86M | 14.63M | 13.14M | 15.01M | 17.02M | 15.92M |
| Operating Income | 239.00K | 585.00K | -13.76M | -12.65M | -888.00K | -7.14M | -9.49M | -9.56M | -7.65M | 17.25M | -10.09M | -2.93M | -2.89M | -3.32M | -2.88M | -1.53M | -1.49M |
| Net Income | 29.00K | 268.00K | -11.87M | -10.65M | -1.38M | -7.53M | -10.08M | -10.14M | -8.36M | 16.79M | -10.44M | -3.36M | -2.39M | -4.07M | -3.80M | -2.31M | -2.23M |
| Diluted EPS | 0.00 | 0.02 | -1.30 | -1.16 | -0.08 | -0.43 | -0.57 | -0.57 | -0.46 | 0.80 | -0.53 | -0.17 | -0.12 | -0.18 | -0.16 | -0.09 | -0.08 |
| R&D Expense | - | - | 29.00K | 718.00K | 1.27M | 2.61M | 2.81M | 2.03M | 1.77M | 2.23M | 7.88M | 913.00K | 842.00K | 39.00K | - | 287.00K | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 44.53M | 63.13M | 71.00M | 59.66M | 55.13M | 61.24M |
| Operating Income | 7.85M | -34.88M | -27.52M | -2.07M | -13.68M | -8.17M |
| Net Income | 5.28M | -43.99M | -29.63M | -3.85M | -14.67M | -11.43M |
| Diluted EPS | 0.49 | -4.32 | -1.69 | -0.21 | -0.72 | -0.47 |
| R&D Expense | - | 2.74M | 10.94M | 7.54M | 9.86M | 480.00K |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 51.91M | 97.28M | 105.16M | 76.85M | 80.24M | 94.59M |
| Total Equity | 2.75M | 10.29M | 42.04M | 16.98M | 20.35M | 20.07M | 31.85M |
| Cash & Equivalents | - | 8.25M | 49.08M | 32.00M | 27.44M | 20.30M | 24.09M |
| Long Term Debt | - | - | - | 19.83M | 14.62M | 24.88M | 25.28M |
| Total Liabilities | - | 41.61M | 55.24M | 88.18M | 56.50M | 60.17M | 62.74M |
| Current Liabilities | - | 28.06M | 51.61M | 66.83M | 41.87M | 35.17M | 37.44M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 5.13M | - | -13.53M | 5.24M | -9.13M | -12.44M |
| Investing Cash Flow | -1.20M | - | -20.00M | -5.00M | -15.00M | 0 |
| Financing Cash Flow | -487.00K | - | 16.46M | -4.80M | 16.99M | 16.23M |
| Capital Expenditure | - | -10.00M | -20.00M | -5.00M | -15.00M | - |
| Free Cash Flow | - | - | -33.53M | 240.00K | -24.13M | -12.44M |
| Net Change in Cash | - | - | -17.08M | -4.56M | -7.13M | 3.79M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | 17.6% | -55.2% | -38.8% | -3.5% | -24.8% | -13.3% |
| Net Margin % | 11.9% | -69.7% | -41.7% | -6.5% | -26.6% | -18.7% |
| ROE % | 51.3% | -104.6% | -174.5% | -18.9% | -73.1% | -35.9% |
| ROCE % | 32.9% | -76.4% | -71.8% | -5.9% | -30.3% | -14.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Wasatch Advisors LP | 9.91% | 2.13M | $15.04M |
| 2 | Tang Capital Management, LLC | 7.48% | 1.61M | $11.35M |
| 3 | Vanguard Capital Management LLC | 5.02% | 1.08M | $7.63M |
| 4 | Blackrock Inc. | 4.52% | 972.86K | $6.86M |
| 5 | Opaleye Management Inc. | 4.46% | 960.00K | $6.77M |
| 6 | J. Goldman & Co., L.P. | 2.32% | 500.19K | $3.53M |
| 7 | Pale Fire Capital SE | 2.24% | 481.99K | $3.40M |
| 8 | Geode Capital Management, LLC | 2.15% | 463.20K | $3.27M |
| 9 | UBS Group AG | 1.81% | 390.14K | $2.75M |
| 10 | Millennium Management Llc | 1.78% | 383.07K | $2.70M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DERM
Journey Medical (DERM) Stock Draws Fresh Price Target Split After Fortress Valuation Changes - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxOS0drb2N0b0xKQ3F1U3BVelBTN1h3SENMSUR5Ry1pbVZKdGxEY0JiMlEzeHB5WnIyMGstbEptLXNFWUpwT0xld0lyMHdMamxCVWNDblp1ZzR2SnA4NVA1MlhnV1lSMlR3a2N0MFZCdFBoeUVpYnNLeHNNY0VzYUduUW9tMGxBeS1WaFVyU0…
Trading the Move, Not the Narrative: (DERM) Edition - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxNSmhodzdVQ2tjVWN5Q3A0N0F6Z01UU25UWjlfQVdQVVlKZmI5SmgxX21tdFdpakdMRFVyemdMUzhUbnZhOXRHTklJMHEyeTdYM29LVy1CSUhXWmVtdDAyY0MyM054d2x4VkVHSGRUeU5yVlVVQ3I2TWtkT2U0RmtxbUNwczBRd25zT2JvN1…
Price to book forward of Journey Medical Corporation – NASDAQ:DERM - TradingView
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxOWmlMOW14NHpUb0hBUVZfNUF0ajk1c3IzX3hsSVFib19UUDI4dVVBMlRROVdDcnR0UER3aUp5YzdkaWI2VmZUWWFsSFF0VDhJeUVMek5tenJjYS1UR0NtVXJMOUNIN1JGLXhRLXhGMkYxV2cxTXlkeDVjSHpYeUFtUjl4S1JmSWJlM1Q5MD…
DERM Stock Price, Quote & Chart - ChartMill
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE03cXNHNTBmUDNDc3ZYMXlhR25TR1FfcXJyMnlKa2hXV2ZCRnA3b3dBSWp0Qm93NXhzRU1RZm9obWJWM1ZJNzB5RXd0T0xyYVhPREFiXzRtRWhUUEdpU0hn?oc=5" target="_blank">DERM Stock Price, Quote & Chart</a>&nbs…
Journey Medical Corporation (NASDAQ:DERM) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxQVjdqbUhMa1R0M00tWWFlRWFBNk45bVZqcDRKeVV2OTl5bG9fcVk1b01XZTF4ZTRLRUNfcmRiUnpUcW1jbzE1NDgxbW1BRDJBODVUYVJDVi0wWWdoUXk2ajZmQTF3cENpdU42WjU3cS1oeGZrUjBKZy1CazZ2aGFjNk15SzhJb29TZG1oY0…
Journey Medical (DERM) grants 50,000 restricted stock units to director - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxQNHRCRmEweUNTWkhSNE5wMjNxMDdUU2UtUTNNSzd1VVVjcm9iekluY0tGUFFqMXN2eElsZE5JYkEtLWtpWVhTQ1BxaUNpU1ZsLW9NeTBCd1Z6ZFlaNzZwbG9OVWNlVENybUhhZmVYSTczRVV1WmNCLUltVGl6cXJXQzlnT1N0NXJwQUpiRF…
DERM — Frequently Asked Questions
What is the current share price of Journey Medical Corporation (DERM)?
As of 2026-07-14 21:23 PDT, Journey Medical Corporation (DERM) trades at $7.12 on NasdaqCM. Its 52-week range is $4.39 to $9.26.
What is the market capitalisation of DERM?
Journey Medical Corporation (DERM) has a market capitalisation of $153.33M on NasdaqCM.
What is the P/E ratio of DERM?
DERM trades at a trailing price-to-earnings (P/E) ratio of -19.24. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 5.62.
What is the return on equity (ROE) of DERM?
DERM has a return on equity (ROE) of -36.62%. Its return on capital employed (ROCE) is -14.30%.
Is DERM a good stock to buy?
This page provides a data-driven analysis of Journey Medical Corporation (DERM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.